Could an immunotherapy cocktail wipe out stomach cancer before surgery?

NCT ID NCT04736485

Completed Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 20, 2026 · Updated 5 times

Summary

This study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) before and after surgery could help people with resectable stomach cancer. 67 adults with early-stage, operable stomach or gastroesophageal junction cancer received the combination. The main goal was to see if the cancer completely disappeared in the tissue removed during surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

APHM Marseille

Marseille, France
APHP St Louis

Paris, France
CH St Malo

St-Malo, France
CHU Besançon

Besançon, France
CHU Poitiers

Poitiers, France
CHU Robert Debré

Reims, France
Centre Eugène Marquis

Rennes, France
Centre François Baclesse

Caen, France
Centre Georges Francois Leclerc

Dijon, France
Chru Lille

Lille, France
ICO St Herblain

Saint-Herblain, France
Institut Mutualiste Montsouris

Paris, France
Institut Régional Cancer

Montpellier, France

Conditions

Explore the condition pages connected to this study.

GASTRIC CANCER BY AJCC V8 STAGE RESECTABLE CARCINOMA